Alzheimer's drug that slows disease gets backing from FDA advisers

FILE - A U.S. Food and Drug Administration building is seen behind FDA logos in Silver Spring, Maryland, on Aug. 2, 2018. FILE - A sign for Eli Lilly & Co. sits outside their corporate headquarters in Indianapolis on April 26, 2017.

A closely watched Alzheimer's drug from Eli Lilly won the backing of federal health advisers Monday, setting the stage for the treatment's expected approval for people with mild dementia caused by the brain-robbing disease.